Elicio Therapeutics Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002, to treat or prevent a range of diseases; ELI-003 for cancers involving an ALK mutation; ELI-011 for hematological cancers; ELI-005, a product for the prevention of COVID-19; and ELI-002 7P (AMPLIFY-7P), a vaccine for mutated solid tumors. The company's AMP platform enables to develop differentiated treatment modalities including therapeutic vaccines, adjuvants, and cell therapy AMPlifiers. The company was formerly known as VEDANTRA PHARMACEUTICALS, INC. and changed its name to Elicio Therapeutics Inc. on September 18, 2019. The company was incorporated in 2011 and is headquartered in Boston, Massachusetts. Show More...